new-molecular-drivers-in-nsclc-the-role-of-met
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | PNAS
Cancers | Free Full-Text | Targeting MET Amplification as a New Oncogenic Driver
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
What Is MET? - MET Crusaders
Targeted Therapies Expanding for MET Dysregulation in NSCLC - ILCN.org (ILCN/WCLC)
![PDF] Targeting MET in Lung Cancer: Will Expectations Finally Be MET? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5c15af3c1bcc3bda3026ee7e5197328b2b922d57/5-Table1-1.png "PDF] Targeting MET in Lung Cancer: Will Expectations Finally Be MET? | Semantic Scholar")
PDF] Targeting MET in Lung Cancer: Will Expectations Finally Be MET? | Semantic Scholar
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer - Aguado - 2021 - Molecular Oncology - Wiley Online Library
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision - ScienceDirect
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - ScienceDirect
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
IJMS | Free Full-Text | Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
MET gene analysis by next-generation sequencing & fluorescence | Oncotarget
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy | Journal of Medicinal Chemistry
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
